BioCentury
ARTICLE | Company News

FDA approves Aralez's Yosprala

September 15, 2016 7:00 AM UTC

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ; TSX:ARZ) said FDA approved an NDA for Yosprala 325/40 ( PA32540) and Yosprala 81/40 ( PA8140) to prevent cardiovascular and cerebrovascular events in patients who require aspirin and are at risk of developing gastric ulcers.

Aralez said it will launch Yosprala next month at a wholesale acquisition cost (WAC) of $150 per 30-count bottle. The tablets contain aspirin and an immediate-release coating of 40 mg omeprazole, a proton pump inhibitor (PPI). Yosprala 325/40 has 325 mg aspirin, while Yosprala 81/40 has 81 mg. ...